SoftBank is set to invest $1.2bn in Invitae, a medical genetics company. Besides SoftBank, a small group of investors will participate. Under the terms of the investment, the participating investors will purchase a total aggregate principal amount of $1.2bn in Convertible Senior Notes due 2028. "Invitae has a definitive head start in the rapidly expanding market for clinical genetic sequencing. Their comprehensive diagnostic products are well positioned to further grow the global understanding of how genomics predispose populations for certain diseases. These datasets will inform treatment and dramatically improve patient outcomes," Akshay Naheta, SB Management CEO.